|Bid||166.05 x 1000|
|Ask||0.00 x 1000|
|Day's Range||168.02 - 175.99|
|52 Week Range||44.05 - 175.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.57|
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Both Loxo Oncology and Jounce Therapeutics shares went in different directions after traders absorbed abstract reveals from each company. Shares of Loxo soared ...
Loxo Oncology Inc. shares surged 20.8% in heavy Thursday morning trade after the company released a preview of early data for its cancer drug LOXO-292. The data, which will be presented at the American Society of Clinical Oncology's annual meeting in early June, looks at interim data from an ongoing phase 1 clinical trial for LOXO-292. The results were impressive, with apparently "unremarkable" safety data, said Stifel analyst Stephen D. Willey, who now expects peak U.S. sales for the drug of more than $800 million.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Walmart Inc (NYSE: WMT ) was trading higher by nearly ...
An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday. The drug, LOXO-292, was well tolerated by patients with advanced cancer, many of whom were resistant to or no longer being helped by available treatments, researchers reported. Loxo shares rose more than 9 percent after the data was released, while shares of Blueprint Medicines, which is developing a rival drug, fell more than 12 percent.
Dow Jones futures fell Thursday. Cisco Systems and Take-Two Interactive, both near buy points, fell on earnings. Loxo Oncology spiked on cancer drug trial data.
–LOXO-292 Phase 1 Clinical Trial Abstract Selected for“ Best of ASCO”–. –Company to Host Conference Call and Webcast on Saturday, June 2 nd at 4:00 p.m. CT–. STAMFORD, Conn., May 16, 2018-- Loxo Oncology, ...
-LOXO-292 Phase 1 Oral Presentation Upcoming at 2018 ASCO Annual Meeting-. -LOXO-292 Preclinical and Clinical Proof-of-Concept Data Published in Annals of Oncology-. -Rolling Submission for Larotrectinib ...
Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that between April 23, 2018 and May 7, 2018, the Compensation Committee of Loxo Oncology’s Board of Directors granted non-qualified stock options to purchase an aggregate of 98,525 shares of its common stock to thirteen new employees.
STAMFORD, Conn., May 01, 2018-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...
Last Sunday, lots of people were gushing about Blueprint Medicines' experimental cancer drug. The answer: biotech fund managers are paying attention to a scientist who poked holes in Blueprint's data on-stage at the annual meeting of the American Association for Cancer Research, the same venue where Blueprint presented its data. Loxo's shares are up 8% since Blueprint's data were presented.
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Clovis Oncology saw its shares close down over 10% on Monday after announcing that it has commenced two separate underwritten public offerings. Shares of Loxo ...
Loxo Oncology Inc (NASDAQ: LOXO ) holds an opportunity to differentiate itself among RET inhibitors while developing medicines for patients with genetically defined cancers, according to Morgan Stanley. ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, April 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types. The companies said the partnership will seek approval for a version of Illumina's test, TruSight Tumor 170, which will allow local laboratories to provide referring physicians with comprehensive genomic information, so that patients can be matched to the most appropriate therapeutic options. Larotrectinib directly targets an acquired rather than inherited genetic defect called TRK fusions.
Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday. The partnership will seek approval for a version of the Illumina's test, TruSight Tumor 170, as a companion diagnostic for Loxo's larotrectinib and another one of Loxo's experimental cancer drugs, across tumor types.
Illumina, Inc. and Loxo Oncology today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing based companion diagnostic with a pan-cancer indication.
-Expands Illumina’ s Oncology Offerings for NextSeq™ 550 Dx with a Companion Diagnostic Version of TruSight™ Tumor 170 for Solid Tumors-. -Loxo Oncology to Utilize a Companion Diagnostic Version of TruSight ...